EP2709614A4 - Pharmazeutische zusammensetzung und verfahren zur behandlung von krebs - Google Patents

Pharmazeutische zusammensetzung und verfahren zur behandlung von krebs

Info

Publication number
EP2709614A4
EP2709614A4 EP12785724.1A EP12785724A EP2709614A4 EP 2709614 A4 EP2709614 A4 EP 2709614A4 EP 12785724 A EP12785724 A EP 12785724A EP 2709614 A4 EP2709614 A4 EP 2709614A4
Authority
EP
European Patent Office
Prior art keywords
methods
pharmaceutical compositions
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12785724.1A
Other languages
English (en)
French (fr)
Other versions
EP2709614A1 (de
Inventor
Oliver Rosen
Iain James Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of EP2709614A1 publication Critical patent/EP2709614A1/de
Publication of EP2709614A4 publication Critical patent/EP2709614A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP12785724.1A 2011-05-17 2012-05-17 Pharmazeutische zusammensetzung und verfahren zur behandlung von krebs Withdrawn EP2709614A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486851P 2011-05-17 2011-05-17
US201161538246P 2011-09-23 2011-09-23
PCT/US2012/038292 WO2012158884A1 (en) 2011-05-17 2012-05-17 Pharmaceutical compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
EP2709614A1 EP2709614A1 (de) 2014-03-26
EP2709614A4 true EP2709614A4 (de) 2015-04-15

Family

ID=47177338

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12785724.1A Withdrawn EP2709614A4 (de) 2011-05-17 2012-05-17 Pharmazeutische zusammensetzung und verfahren zur behandlung von krebs

Country Status (7)

Country Link
EP (1) EP2709614A4 (de)
JP (1) JP2014513730A (de)
AR (1) AR086444A1 (de)
CA (1) CA2836277A1 (de)
TW (1) TW201309291A (de)
UY (1) UY34078A (de)
WO (1) WO2012158884A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
AR083916A1 (es) * 2010-11-18 2013-04-10 Takeda Pharmaceutical Metodo para tratar el cancer de mama y cancer de ovarios
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20160022606A1 (en) * 2013-03-14 2016-01-28 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
EP3824908A1 (de) 2015-04-10 2021-05-26 Capsugel Belgium NV Abirateron-acetat-lipidformulierungen
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100261689A1 (en) * 2007-10-29 2010-10-14 Masuo Yamaoka Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
CN101460467B (zh) * 2006-03-29 2012-09-19 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100261689A1 (en) * 2007-10-29 2010-10-14 Masuo Yamaoka Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012158884A1 *

Also Published As

Publication number Publication date
CA2836277A1 (en) 2012-11-22
JP2014513730A (ja) 2014-06-05
TW201309291A (zh) 2013-03-01
EP2709614A1 (de) 2014-03-26
WO2012158884A1 (en) 2012-11-22
AR086444A1 (es) 2013-12-11
UY34078A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
HK1209798A1 (en) Compositions and methods for treating cancer
IL227429A0 (en) The components and methods of cancer treatment
EP2755482A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP2836482A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP2890720A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
IL234989B (en) Compounds and preparations containing them for the treatment of cancer
EP2771341A4 (de) Neue zusammensetzungen und verfahren zur behandlung von krebs
EP2688594A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP2709614A4 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von krebs
SG10201500124VA (en) Methods and Compositions for Treating Cancer
DK3292875T3 (en) Compositions and methods for treating diseases
HK1202248A1 (en) Compositions and methods for treating neurodegenerative disease
HK1202246A1 (en) Compositions and methods for treating neurodegenerative disease
IL229231A0 (en) Preparations and methods for the treatment of cancer
HK1216854A1 (zh) 用於治療癌症的組合物和方法
EP2823825A4 (de) Pharmazeutische zusammensetzung zur krebsbehandlung
EP2717865A4 (de) Verfahren und zusammensetzungen zur behandlung von hirnkrebs
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2863939A4 (de) Zusammensetzungen und verfahren zur behandlung von vitiligo
HK1188566A1 (zh) 治療癌症的組合物和方法
EP2928456A4 (de) Verfahren und zusammensetzungen für die behandlung von krebs
EP2582384A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP2537031A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
HK1207561A1 (en) Compositions and methods for treating hepatocellular cancer
PL2663318T3 (pl) Kompozycja farmaceutyczna do leczenia raka

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150317

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20150311BHEP

Ipc: A61K 31/4164 20060101ALI20150311BHEP

Ipc: A61K 31/40 20060101AFI20150311BHEP

Ipc: A61K 45/06 20060101ALI20150311BHEP

Ipc: A61K 31/00 20060101ALI20150311BHEP

Ipc: A61P 35/04 20060101ALI20150311BHEP

Ipc: A61K 31/4188 20060101ALI20150311BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151020